Form 4 for AIDX 20/20 Biolabs, Inc.
Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-19 · accession 0001213900-26-019421 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-23 | 2026-02-19 | AIDX | COHEN RICHARD M | Dir | C - Cnv Deriv | $0.00 | +7,700 | 7,700 | New | $0 |
| D | 2026-02-23 | 2026-02-19 | AIDX | COHEN RICHARD M | Dir | C - Cnv Deriv | — | -7,700 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-19 | C | A | 7,700 | $0.00 | 7,700 | D | — | — | |
| 2 | Derivative | Series A-2 Preferred Stock | 2026-02-19 | C | D | 7,700 | — | 0 | D | — · — to — | 7,700 Common Stock | (F1) On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |